These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
954 related articles for article (PubMed ID: 34373896)
1. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R; Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896 [TBL] [Abstract][Full Text] [Related]
2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052 [TBL] [Abstract][Full Text] [Related]
3. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815 [TBL] [Abstract][Full Text] [Related]
4. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874 [TBL] [Abstract][Full Text] [Related]
5. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000 [TBL] [Abstract][Full Text] [Related]
7. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829 [TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820 [TBL] [Abstract][Full Text] [Related]
9. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K; Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117 [TBL] [Abstract][Full Text] [Related]
10. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA; Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519 [TBL] [Abstract][Full Text] [Related]
11. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
12. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714 [TBL] [Abstract][Full Text] [Related]
13. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease. Yan S; Zheng C; Paranjpe MD; Li J; Benzinger TLS; Lu J; Zhou Y Theranostics; 2020; 10(23):10563-10572. PubMed ID: 32929366 [TBL] [Abstract][Full Text] [Related]
14. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523 [TBL] [Abstract][Full Text] [Related]
15. APOE effects on regional tau in preclinical Alzheimer's disease. Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ; Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122 [TBL] [Abstract][Full Text] [Related]
16. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077 [TBL] [Abstract][Full Text] [Related]